Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

① During the earnings conference, fosun pharma stated that the company's performance improved year-on-year in Q3 due to factors such as the continuous increase in innovative drug volume. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the rapid上市 and sales of injectable type A botulinum toxin within china. ③ The privatization process of henlius and the accessibility of CAR-T products are also receiving significant attention.

cls.cnNov 13 21:52

Investors are paying attention to the progress of FT606. shandong lukang pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference.

①The progress of the company's new synthetic biotechnology material product FT606 has attracted much attention. ②The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 earnings. ③During the earnings conference, a questioner who claimed to be an investor expressed dissatisfaction with the lack of interaction.

cls.cnNov 8 21:51

Hubei Guangji Pharmaceutical was investigated by the CSRC for disclosure violations and was warned in November last year. | Quick read announcement

Tonight, hubei guangji pharmaceutical announced that it is under investigation by the China Securities Regulatory Commission for suspected violations of disclosure regulations; In May of this year, hubei guangji pharmaceutical experienced a wave of rising market trends; Currently, hubei guangji pharmaceutical is deeply trapped in poor performance.

cls.cnOct 25 19:25

Jiangsu Hengrui Pharmaceuticals' Q3 revenue was 6.59 billion yuan, with a net income of 1.19 billion yuan, a slight year-on-year increase of 1.9%. | Financial Report Watch

In the third quarter, jiangsu hengrui pharmaceuticals' eps was 0.19 RMB, a year-on-year increase of 5.56%. In the first three quarters, jiangsu hengrui pharmaceuticals' profit increased by 32.98% year-on-year, with eps increasing by 32.73% year-on-year. The main reason is that the company recognized the upfront payment received from Merck Healthcare of 0.16 billion euros as revenue, which significantly increased the profit.

wallstreetcnOct 24 19:58

From cspc innovation pharmaceutical to Stone Medicine Innovation, what has changed is not just the R&D expenses.

From active pharmaceutical ingredients to innovative drugs, from focusing on current profits to focusing on product pipeline and cash flow.

wallstreetcnOct 24 16:25

"Pharmaceuticals king" for financing or listing in Hong Kong? Jiangsu Hengrui Pharmaceuticals has no comment on the rumors.

①There were reports last night that jiangsu hengrui pharmaceuticals is considering a secondary listing in Hong Kong next year, with an expected fundraising amount of 2 billion US dollars. In response, jiangsu hengrui pharmaceuticals stated that they have no comments; ② Industry insiders believe that a secondary listing in Hong Kong can not only raise funds but also enhance the company's international influence.

cls.cnOct 24 14:03